Clinical validation results of an innovative non-invasive device for colorectal cancer preventive screening through fecal exhalation analysis

Screening is recommended to reduce both incidence and mortality of colorectal cancer. Currently, many countries employ fecal occult blood test (FOBT). In Emilia-Romagna (Italy), since 2005, FOBT immunochemical version (FIT) is performed every two years on people aged between 50 and 69 years. A colonoscopy is then carried out on those who are FIT positive. However, FIT shows approximately 65% false positives (non-tumoral bleedings), leading to many negative colonoscopies. The use of an economic and easy-to-use method to check FOBT-positives will improve screening effectiveness, reducing costs to the national health service. This work illustrates the results of a three-year clinical validation protocol (started in 2016) of a patented device composed of a core of nanostructured gas sensors. This device was designed to identify CRC presence by fecal volatile compounds, with a non-invasive, in vitro and low-cost analysis. Feces are, in fact, affected by tumor-volatile biomarkers, produced by cellular peroxidation and metabolic alterations. The protocol consisted in the analysis of fecal samples of FIT-positive subjects, using colonoscopy as a gold standard. A total of 398 samples were analyzed with machine learning techniques, leading to a sensitivity and specificity of 84.1% and 82.4%, respectively, and a positive predictive value of 72% (25–35% for FIT)

Field evaluation of Bt cotton crop impact on nontarget pests: cotton aphid and boll weevil.

Made available in DSpace on 2018-07-01T01:26:24Z (GMT). No. of bitstreams: 1 art3A10.10072Fs1374401200940.pdf: 255052 bytes, checksum: 0eecda39292292a10208a82621fb821b (MD5) Previous issue date: 2013-08-13bitstream/item/156260/1/art3A10.10072Fs13744-012-0094-0.pd

Princípios e práticas ecológicas para o manejo de insetos-praga na agricultura.

bitstream/item/109190/1/1112-05-nco-folderPrincipiosPraticasEcologicas.pd

Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition

Targeted inhibitors of JAK2 (eg ruxolitinib) often provide symptomatic relief for myeloproliferative neoplasm (MPN) patients, but the malignant clone persists and remains susceptible to disease transformation. These observations suggest that targeting alternative dysregulated signaling pathways may provide therapeutic benefit. Previous studies identified NFκB pathway hyperactivation in myelofibrosis (MF) and secondary acute myeloid leukemia (sAML) that was insensitive to JAK2 inhibition. Here, we provide evidence that NFκB pathway inhibition via pevonedistat targets malignant cells in MPN patient samples as well as in MPN and patient-derived xenograft mouse models that are nonredundant with ruxolitinib. Colony forming assays revealed preferential inhibition of MF colony growth compared with normal colony formation. In mass cytometry studies, pevonedistat blunted canonical TNFα responses in MF and sAML patient CD34+ cells. Pevonedistat also inhibited hyperproduction of inflammatory cytokines more effectively than ruxolitinib. Upon pevonedistat treatment alone or in combination with ruxolitinib, MPN mouse models exhibited reduced disease burden and improved survival. These studies demonstrating efficacy of pevonedistat in MPN cells in vitro as well as in vivo provide a rationale for therapeutic inhibition of NFκB signaling for MF treatment. Based on these findings, a Phase 1 clinical trial combining pevonedistat with ruxolitinib has been initiated

Manipulação do habitat em diferentes escalas espaciais para o controle biológico conservativo em hortaliças orgânicas.

Suplemento. Edição dos Anais do 10 Congresso Brasileiro de Agroecologia; 6 Congresso Latino-americano de Agroecologia; 5 Seminário de Agroecologia do Distrito Federal e Entorno, Brasília, DF, set. 2017. Na publicação: Sujii, Edison; Souza, Lucas; Sousa, Ale